Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87.4M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
+15.6M
-
Total reported value, excl. options
-
$178M
-
Value change
-
+$107M
-
Number of buys
-
33
-
Number of sells
-
-17
-
Price
-
$5.89
Significant Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q3 2022
53 filings reported holding TERN - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2022.
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
of 87.4M outstanding shares and own 34.58% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.48M shares), Vivo Capital, LLC (5.9M shares), VR Adviser, LLC (3.71M shares), Fairmount Funds Management LLC (2.05M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.86M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (1.6M shares), JPMORGAN CHASE & CO (919K shares), Ikarian Capital, LLC (904K shares), PURA VIDA INVESTMENTS, LLC (729K shares), and Decheng Capital Management III (Cayman), LLC (714K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.